What if the solution is hidden in your data?

Biomax understands the challenges of using big, complex data to address complicated problems in an ever-changing world.

Model your scientific world for fully interactive, deep analysis. Critical connections that were not previously apparent become clear.

Knowledge Management for the Life Sciences

What if you could mobilize your entire organization’s collective knowledge?

The Biomax approach transforms the way organizations combine, share and act on their information resources.

With Biomax, the whole organization benefits from better-informed planning, faster decision-making and more innovative thinking.

Knowledge Management for the Life Sciences

What if your organization ran smoothly even through disruptive change?

Biomax helps organizations evolve as quickly and efficiently as possible.

Biomax technology integrates into exisiting IT environments to connect and manage all resources and analysis tools securely. It easily adapts when circumstances or new technologies require the organization to change.

Knowledge Management for the Life Sciences

Take advantage of our solutions across various sectors in the Life Sciences

Flexible software to solve complex problems

Biomax computational solutions have helped clients manage their knowledge assets and use them to make better decisions, develop innovative products and find new ways to solve complex problems. While Biomax has proven expertise in several life science sectors, Biomax solutions are increasingly applied to new areas by the most innovative organizations in the world.

Partner for innovative research

Biomax has provided custom-designed software solutions in over 20 international research projects with thousands of end-users each day. With these vast, multidisciplinary projects, Biomax continuously gains insight into the most innovative and relevant research and development happening today. At the same time, this insight expands our expertise in data integration and knowledge management.

Client-focused knowledge management solutions

Biomax clients include some of the most innovative life science and health care facilities in the world. Biomax has developed flexible solutions for a wide range of clients: small to large multinational organizations in industry, academia, government and the non-profit sector.

Experience our products

BioXM™ Knowledge Management Environment

The BioXM™ Knowledge Management Environment is a fully customizable, all-in-one enterprise knowledge management system for better integrated, evidence-based research and development.

Turn knowledge into an asset

The BioXM platform provides a central inventory of all the information representing an organization's collective knowledge. While individuals focus on generating knowledge in their specific fields of expertise, the whole organization can benefit from that knowledge to make better decisions and follow more intelligent strategies.

The BioXM platform allows quick configuration of highly customized solutions that are driven by specific research and business needs. The knowledge model can continuously adapt to new information or circumstances, which leads to more agility in the face of change, a higher ROI, and ultimately more stability and success.

BioXM

The BioXM system is a project-centered, distributed platform that allows isolated sources of information to be connected into a central inventory of information and knowledge. Users create, manage and visualize scientific models as extendible networks representing an area of research or a particular perspective. Through semantic modeling of these interrelated concepts, all perspectives are integrated into the knowledge network and relationships that were previously hidden become clear.

Turn knowledge into an asset

Personalized user interfaces and flexible access support diverse users and project groups. Individuals can focus on their science and generating knowledge in their field of expertise while the whole organization can deploy it to gain insight, make better decisions and innovate faster.

The BioXM platform integrates seamlessly into diverse computing environments and ensures secure and efficient data sharing among team members within distributed environments.

The following are a few examples of how the BioXM system has been used. You can get all of them and more in a single solution. The possibilities are virtually limitless.

  • Connect and explore clinical data, study information and statistical analyses
  • Keep non-redundant repositories of scientific data such as: experimental results, a corporate gene index, a patient register, a phenotype catalog, or a compound and drug database
  • Create comprehensive disease maps based on automatic literature mining results
  • Connect, organize, review, compare, annotate and modify biological pathways originating from different sources
  • Identify biomarker candidates based on automatic literature analysis and compare the results to experimental findings in one platform
  • Classify biological functions using ontologies specific to focused scientific areas
  • Easily integrate external statistical packages (R, BioConductor), bioinformatics tools, chemoinformatics algorithms, Web services and more
  • Generate networks from multiple sources and find previously undetected links in the data
  • Keep track of ongoing projects with one click to generate smart folders, table reports and overview graphs

BioRS™ Integration and Retrieval System

The BioRS™ Integration and Retrieval System system offers a secure way to leverage vast quantities of diverse, distributed data and discover what the competition cannot.

Empower your research

The BioRS Integration and Retrieval System is the next-generation content integration and search tool for users who require fast, flexible and efficient management of multiple data resources. Especially adapted to the diversity and complexities of life science data, the new BioRS search engine provides all needed functionality in a single, user-centered interface. Users easily find their way to any kind of resource, faster than ever before.

BioRS

The BioRS™ Integration and Retrieval System seamlessly and efficiently combines biological data from proprietary databases with public or licensed resources, independent of size or location.

The basic BioRS installation maintains a collection of up-to-date public databases, allowing users to immediately share data, perform complex queries and analyze the results in different ways. Clients select from the set of standard life science databases and can integrate additional resources — whether in-house, federated or external — to fit their specific needs. Flat-file and relational databases (including Oracle®, MySQL® and Microsoft® SQL Server®) as well as structured file formats can be integrated securely.

All resources can be simultaneously searched within a unified interface and are kept up-to-date based on user-defined schedules. The BioRS system comes equipped with search concepts like global, proximity and fuzzy searches, and can be customized with domain-specific queries and result views.

The BioRS system integrates seamlessly into diverse computing environments and ensures security within distributed environments and safe, efficient data sharing among team members in multiple locations.

The BioRS system helps all users — whether occasional, daily or expert — tame vast quantities of diverse data, identify critical information and find the best avenues to pursue.

  • Quickly and seamlessly search all data available in a single unified interface
  • Efficiently combine proprietary data with public and licensed databases, including both flat-files and relational databases
  • Standardize data formats and integrate large-scale, heterogeneous life science and medical data from different sources
  • Coordinate data, processes and projects across multiple departments and facilities to reduce redundant work
  • Connect large teams and share data securely by assigning group-specific roles or privileges to individual users
  • Schedule user-specific automatic updating of data resources

Viscovery™Data Mining Suite

The Viscovery® Data Mining Suite provides a powerful visual approach to high-performance data mining and predictive modeling.

Viscover your data

The Viscovery software provides data scientists as well as business users with a versatile and powerful set of data mining tools. Even users without a statistical background can visualize highly complex data sets, recognize dependences and create predictive models.

The Viscovery software was developed based on a deep understanding of analytical methods in a wide variety of industries. Even the most complex medical and life science data become easier to interpret and use.

VISCOVERY

Using the combined power of self-organizing maps (SOMs) and robust statistics, Viscovery technology allows users to represent huge quantities of information on a single screen and visually reveal the essence of complex data.

Turn knowledge into an asset

Guided by workflows, users import their data and build models that enable visual exploration of clusters and dependences. Statistical methods and advanced analytics can be deployed for predictive modeling, classification and forecasting of processes and outcomes based on key attributes. The Viscovery suite provides multiple capabilities to define segmentation and scoring, to test and validate models, and to evaluate the application results. Workflow branching allows the generation of model variations for comparison, exploration and hypothesis generation.

Viscovery models can be shared easily to enrich decision making with visual information — so you can use all your data to increase productivity, effectiveness and gain a competitive advantage.

For over 20 years, Viscovery technology has been deployed in a wide variety of industries. In the life sciences and medical fields, it enables the following:

  • Perform gene expression analysis
  • Explore biological data patterns and identify biomarkers
  • Improve medical diagnostics and pathological classification
  • Analyze patient risk, treatment and prescription costs
  • Optimize healthcare systems
  • Improve clinical research
  • Stream-line biotechnology processes

Pedant-Pro™ Sequence Analysis Suite

The Pedant-Pro Sequence Analysis Suite is the most stable and dependable solution for genome annotation.

Leverage your sequence data

The Pedant-Pro™ Sequence Analysis Suite performs fast comprehensive, enterprise-scale gene and genome analysis and automatic annotation of large data sets. Deployed in the full enterprise version or used on a subscription basis, the Pedant-Pro software lets you move as quickly as possible from raw sequence to reliable information on protein structure and function.

Pedant Pro

The Pedant-Pro suite performs gene prediction and a detailed characterization of the resulting proteins based on numerous reliable algorithms.

The gene report summarizes the most relevant results and provides links to public databases and corporate data. Protein domains are analyzed and potential functions are revealed. Clusters of paralogous proteins are detected. Two- and three-dimensional structural properties are assigned. Different types of non-coding RNA and DNA features are also predicted, including tRNA, rRNA and more. Graphical DNA, protein and pathway viewers enhance the visualization of the results.

The Pedant-Pro software is delivered with standard workflows which have been pre-defined by Biomax. With powerful scripting interfaces and Web services interfaces, the Pedant-Pro suite easily integrates into complex computing environments and allows further integration of customized workflows and algorithms. Analyses can be efficiently deployed on systems ranging from local machines to industrial-scale computing grids.

The Pedant-Pro subscription service is ideal for shorter-term projects with flexible, pay-as-you-go access and minimal use of computer resources.

With its high-throughput, industrial-scale grid-processing engine, the Pedant-Pro suite offers dozens of benefits. Here are just a few:

  • Process large amounts of sequences with multi-method analysis in minimum time
  • Produce comparable results over numerous analyses
  • Create an organization-wide sequence, target, gene or protein repository with manual annotation and curation
  • Provide a central index allowing all scientists to access and annotate information from distributed locations
  • Integrate and analyze high-throughput single nucleotide polymorphism (SNP) data
  • Easily find potential diagnostic and drug targets matching required properties
  • Simplify strain optimization using SNP information

What our clients say about working with Biomax

Say hello to the experts who will make it work

Biomax wants to ensure that you get the most out of your investment. Our experts cover all perspectives involved: from business development, data integration, research and analysis, to software development and deployment of IT. The Biomax team is here to support you through the whole process — from initial conversations, pilot projects, set-up and configuration to support, maintenance and identifying future goals.

Dr. Dieter Maier
Head of Project Management
Dr. Sascha Losko
Head of Product Management
Ralf Jost
Director Technical Bioinformatics



Biomax Newsroom

Biomax plans to be at the following events.
If you would like to meet us at a particular event, please contact us.

25 - 28 September
CAP The Pathologists' Meeting
Wynn Las Vegas and Encore | Las Vegas, NV, USA
more details
18 - 22 October
American Society of Human Genetics (ASHG)
Vancouver Convention Center | Vancouver, BC, Canada
more details
20 - 21 October
15. Europäischer Gesundheitskongress
München Hilton | Munich, Germany
more details
12 - 16 November
Society for Neuroscience (SFN) Annual Meeting
San Diego Convention Center | San Diego, CA, USA
more details

Biomax plans to be at the following events.
If you would like to meet us at a particular event, please contact us.

14 – 18 January
International Plant & Animal Genome XXV (PAG)
Town and Country Hotel | San Diego, CA, USA
more details
19 – 24 February
Molecular Med Tri-Con 2017
Moscone North Convention Center | San Francisco, CA, USA
more details
1 – 5 April
America Association for Cancer Research (AACR)
Walter E Washington Convention Center | Washington, DC, USA
more details

Biomax Knowledge Library – get help, find answers and learn

The best way to learn more is to get in touch and see the Biomax technology in action; the second-best way is to check out our detailed product information, use cases, white papers, publications and more. The Biomax Knowledge Library lets you explore many levels of information: for newbies and novices, skilled and super users, developers and admins.

LOGIN & FIND ANSWERS

The Life Sciences Knowledge Management Company

Management

Biomax Informatics AG was founded in 1997 with a mission to develop software solutions based on the real needs of life science organizations.

Based on 20 years of long-term collaboration with life science clients, we at Biomax are convinced that systematic knowledge management is the key to understand complex processes and help clients get the most from their data resources. We recognized early on that clients need a solution to deal with increasing quantities of unstructured data and have focused development on this goal.

Today Biomax delivers a solution which allows systematic knowledge management: from the digitalization of internal and external data, to the semantic integration of diverse content and methods, and further to the systematic feedback of results and experiences for optimization and sustainability.

The Biomax team has grown continuously in recent years to consist of about 50 multidisciplinary scientists and software engineers. The stability of the Biomax team enables long-term relationships with clients. This longevity is supported by agile solutions that can be extended to cover new use cases or business areas and evolve with the client as their needs grow and change.

Participation in multinational research projects keeps the Biomax team on the leading edge of both research and technology — and ensures that Biomax delivers state-of-the-art solutions to all of their clients.

Hans-Werner Mewes Chairman of the Board of Directors

Professor Dr. Hans-Werner Mewes is one of the co-founders of Biomax and currently serves as Chairman of the Board of Directors. As an active researcher and professor, Mewes has championed scientific leadership in the business development and strategy of Biomax since its inception.

After studying chemistry at Philipps University in Marburg, Mewes has held appointments at the University of Heidelberg, the European Molecular Biology Laboratory (EMBL) and the Max Planck Institute (MPI) for Biochemistry. In 1988, Dr. Mewes founded the Munich Information Center for Protein Sequences (MIPS) to collaborate with partners to build the international PIR Protein Sequence Database. He initiated the bioinformatics study program supported by the German Research Foundation in 1999.

Since 2001, Dr. Mewes has been Professor of Bioinformatics at the Technische Universität München (TUM) and Director of the Institute of Bioinformatics and Systems Biology at the Helmholtz Zentrum München.

Klaus HeumannChief Executive Officer of Biomax

Dr. rer. nat. Klaus Heumann is one of the company’s co-founders and has been Chief Executive Officer of Biomax since its foundation. Heumann has lead the evolution of Biomax from a classic bioinformatics company to one of the leading knowledge management companies for the life sciences and healthcare.

He brought together innovative and highly qualified life scientists, computer scientists and engineers to build a multidisciplinary team that truly understands the diverse challenges and underlying business and R&D processes in the wider life sciences arena.

Dr. Heumann earned his PhD from the Technische Universität München (TUM) and was part of the Munich Information Center for Protein Sequences (MIPS) team that published the first sequenced eukaryotic genome, Saccharomyces cerevisiae. He led the project to compile the results on the yeast genome CD-ROM published by Science and Nature magazines. In 1996, Dr. Heumann received the Heinz Billing Prize of the Max Planck Society for his work on “Identification and visualization of duplications in the yeast genome.”

Dmitrij FrishmanChief Scientific Advisor

Professor Dr. Dmitrij Frishman is one of the co-founders of Biomax and acts as the company’s Chief Scientific Advisor. As an active researcher and recognized expert in computational biology, Dr. Frishman has been responsible for scientific project support and advancing scientific excellence at Biomax since its beginning.

Dr. Frishman developed the Pedant-Pro™ Sequence Analysis Suite, the backbone of the company’s well-established portfolio of genome bioinformatics and systematic computational genome analysis tools.

Dr. Frishman received his PhD in biochemistry from the Russian Academy of Sciences. Since then he has held appointments at the European Molecular Biology Laboratory (EMBL), the Max Planck Institute for Biochemistry and as Deputy Director of the Institute for Bioinformatics at the German National Center for Health and Environment.

Dr. Frishman is currently Professor of Bioinformatics at the Technische Universität München (TUM).

Jonathan SheridanCEO of Biomax Informatics Inc

Jonathan Sheridan acts as CEO of Biomax Informatics Inc., a wholly owned subsidiary of Biomax Informatics AG, and Vice President of Corporate Development and General Manager of Biomax Informatics AG for the Americas and Japan. Sheridan brings a deep understanding of business development and the commercialization of life science products to the Biomax Group.

With over twenty years of sales, marketing and business development experience in the biotechnology industry, Sheridan has held several positions at leading biotech firms. As CCO at Integromics, a Spanish bioinformatics company, he managed global commercial operations and assisted the CEO and the founders with the transfer of global distribution responsibilities to PerkinElmer, Inc. Prior to Integromics, Sheridan was President and Chief Executive Officer with Integrated Genomics, Inc. and held senior positions with PerkinElmer Life and Analytical Sciences, Epicentre Biotechnologies, Genomica, Lion Biosciences, PerkinElmer Cetus, Beckman Coulter and Monsanto.

Gerhard KrannerFounder and Managing Director of Viscovery Software GmbH

Dr. Gerhard Kranner is the founder and managing director of Viscovery Software GmbH (formerly Eudaptics), Biomax’s data mining subsidiary in Vienna, Austria. In 1994, Dr. Kranner founded the company, which was acquired by Biomax in 2007.

As part of the Biomax Group, Dr. Kranner has established the company’s strong analytical capabilities and continues to drive the development of the scalable Viscovery data-mining suite, especially in the life science and healthcare arenas.

Dr. Kranner has a background as theoretical physicist and received his PhD from the Vienna University of Technology.

1997

Biomax Informatics GmbH (“company with limited liability") was founded as spin-off of the Helmholtz Center hosting the Munich Information Center for Protein Sequences (MIPS).

2000

Biomax becomes Biomax Informatics Aktiengesellschaft (AG, “company limited by privately held share ownership”).

2007

The Biomax Group acquires data mining specialists Eudaptics (Austria). Eudaptics becomes Viscovery Software GmbH, renamed after its flagship product.

2011

Biomax enters synthetic biology sector.

2012

Biomax enters the health and clinical market and announces the CIRO+ Data Center enabling patient stratification and targeted medicine in COPD.

2013

Biomax enters the mental health sector developing systems medicine solutions.

2014

Biomax announces expansion of operations in the United States and the opening of its US headquarters near Madison, Wisconsin.

Today

Biomax continues on the path of strong growth in pursuit of its vision to enable anyone to benefit from and contribute to collective know-how, experience and knowledge in the life sciences.

Worldwide
Biomax Informatics AG

Robert-Koch-Str. 2
D-82152 Planegg
Germany
Call: +49 89 895574-0
E-Mail: info@biomax.com

United Kingdom
Biomax Informatics AG

93 Boss House
2 Boss Street
London SE1 2PT
Call: +44 7832 965 326
E-Mail: info@biomax.com

United States
Biomax Informatics Inc.

1101 Highway 69
Suite #5
New Glarus, WI 53574
Call: +1 (608) 636-2098
E-Mail: info@biomax.com

Sophic Systems Alliance, Inc.

200 Main Street, Suite 201
Falmouth, MA 02540
Call: +1 (508) 495-3801
Fax: +1 (508) 495-3805
E-Mail: info@sophicalliance.com
Website: www.sophicalliance.com

Biomax has a well-earned reputation as a premier knowledge management software provider for commercial, academic and government organizations. Our professional staff is dedicated to providing innovative products and services that help our clients get the most out of their resources.

If you are inspired by the opportunities offered by bringing knowledge management to the life sciences, we welcome you to contact us.

×

Respiratory health

Biomax has championed the translation of the systems medicine approach into clinical practice through numerous projects covering respiratory health. From the pioneering BioBridge project to more recent projects like MeDALL and AirPROM, Biomax has developed disease knowledge bases that integrate clinical data, disease information and therapy data with experimental data, image analysis pipelines, computational models, clinical decision support systems and more. These knowledge bases have been used in clinics to support decisions made in diagnosis, prognosis, treatment and prevention.

×

Cancer research

Biomax has contributed to cancer research by providing knowledge bases in several international projects. Biomax built the Cancer Gene Index, a database of gene–disease and gene–drug compound associations mined from the literature, in collaboration with the National Cancer Institute (NCI).

In the area of personalized medicine for cancer, Biomax created a knowledge base for the CANCERMOTISYS project. The knowledge base was designed to support a systems biology approach to find biomarkers that predict treatment success of targeted gastric cancer therapies. It was further expanded in the follow-up project, SYS-Stomach, to support the generation of computational models to validate identified biomarkers. To do this, cell-line-based molecular data was integrated with clinical trial data, making the knowledge base a valuable resource for future research.

×

Mental health

Biomax has invested nearly €1 million to transfer its systems medicine expertise in respiratory and chronic diseases to mental health. Biomax provides the knowledge management platform and data integration for the EU-funded METSY project, which unites collaborators from industry, research and clinics to find links between psychotic disorders, lipid metabolism and metabolism-related diseases like obesity and diabetes.

Biomax has integrated information about brain structure and function, information about psychosis and genetic factors derived from automatic literature mining, brain imaging (combined MRI and PET) data, metabolite profiling, and patient-specific clinical data in a knowledge base that can be mined to identify biomarkers of psychosis. The project aims to bring the results directly into decision support systems in clinical practice.

×

Infectious disease

Biomax provides the knowledge platform for the PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) network, which aims to optimize the response to any severe infectious disease outbreak with real-time information from large-scale clinical research. Biomax provides the BioXM platform to help the network most quickly and efficiently integrate and analyze data and know-how about any emerging infectious disease.

With the BioXM platform, existing disease knowledge, clinical and omics data from the project’s large-scale, patient-oriented pathogenesis research studies are integrated and mapped for a systems medicine approach. Connecting the data in this way gives insight into (personalized) clinical management strategies for patients with acute infections and delivers real-time evidence to help plan better public health responses more quickly — and ultimately save more lives.

×

Health Informatics

Biomax Health Informatics solutions provide both the conceptual and computational infrastructure for an evidence-based and disease-centric approach to healthcare delivery.

Biomax solutions are highly flexible and provide integrated knowledge management and analysis of diverse data using the versatile BioXM platform for patient stratification and targeted therapy.

We enable organizations to achieve the following:

Treating the individual with the knowledge of all

One of the cornerstones of the Biomax approach is patient stratification. Patient stratification involves the use of biomarkers, genetic profiles, research data and clinical information to create subsets within a patient population allowing patients to be grouped in terms of a therapeutic response.

Stratification reaches beyond current statistical patient evaluation methods and epidemiological predictions to integrate and bring thousands of clinical data points as well as intrinsic and extrinsic parameters to the patient evaluation process. The result is better decision making on behalf of the individual patient as well as the healthcare delivery organization — a true win-win situation.

Use case: CIRO+ clinic success

×

Clinical Research

Biomax clinical research solutions help clients make process improvements that move them past stifling inefficiency to realize increased productivity, reduce redundant work and lower costs.

Core Biomax technologies for integrating, managing, mining and analyzing data are used to generate valuable, actionable knowledge and hypothesis modeling for a broad range of clinical research requirements. These solutions empower scientists to quickly identify novel relationships and patterns between biomedical information networks, patient data, clinical trial data, and more — relationships that otherwise may have gone undetected.

Biomax solutions are flexibly tailored to specific client requirements and decision-making processes through configuration, making them ideal for fast-paced research environments. They can be put to productive use much sooner than traditional, time-intensive software development and changes can be implemented while the system stays in productive use.

Use cases: international research projects

In addition to commercial clients, Biomax has pioneered the translation of systems medicine in clinical practice in several research projects. In these projects, Biomax developed disease-specific knowledge bases that integrate clinical data with image analysis pipelines and computational models to generate clinical decision support systems — used for diagnosis, prognosis and eventually prevention.

×

Drug Discovery

More than ever before drug discovery organizations need to develop novel drugs most efficiently, bring them to market most quickly, while keeping costs under control. Extracting useful, actionable information from diverse omics data is a business necessity, but it also poses daunting challenges in drug discovery and development.

With the Biomax drug discovery platform, highly diverse disciplines, disparate data sources and evolving technologies work together in a complementary, mutually supportive and cost-effective way. Supporting the data-intensive and hypothesis-driven processes of drug discovery research in this way helps clients become more productive and get a higher return on investment.

The BioXM™ Knowledge Management Environment combined with the workhorse BioRS™ Integration and Retrieval System provides a flexible and intuitive foundation for discovering novel relationships and patterns in biomedical information networks. Biomax technology significantly cuts the time — and the cost — of developing new drugs from discovery to approval to market, without compromising patient safety or risking regulatory rejection.

Use case: disease maps in drug discovery

The Biomax drug discovery platform is often used to build disease maps that facilitate a systems approach to drug discovery. This is especially useful for diseases with multi-factorial pathologies involving several pathways. A disease map can be a crucial tool for drug repurposing, providing valuable supportive data to regulators for Off-Label Use applications. Disease maps can be augmented even further using the BioXM text mining tool to mine integrated patent data and assist with Freedom-to-Operate decisions.

×

Biomarker Discovery

Biomax biomarker discovery and validation solutions enable scientists to uncover non-obvious associations between data and delineate composite biomarkers across multiple high-throughput experiments for screening, diagnosis and prognosis. Researchers are given the power to connect data using a wide range of proprietary and public technologies, shed light on multifactorial disease phenotypes, and recognize discrete and specific biomarkers which can otherwise go undetected.

Biomax biomarker discovery and validation solutions leverage the BioXM Knowledge Management Environment and the Viscovery Data Mining Suite among other modules to provide integrated analysis, hypothesis modeling and knowledge generation — vital requirements to success in biomarker discovery. Integrated knowledge is combined with data analysis results to rationalize patterns, determine testable hypotheses, make decisions and take action. New data is interpreted in the context of functionally interlinked knowledge (from text, databases, computational models, etc.) and new insights emerge. Scientists can identify novel relationships and patterns in biomedical information networks in combination with exploratory and predictive data mining. In addition, functional modules of dense connectivity form starting points for machine-assisted network generation and analysis for cyclical knowledge discovery.

Biomax solutions support all stages — from biomarker discovery to prioritization to validation and clinical applications — with the following:

×

Agriculture

Biomax solutions for agriculture add a new dimension to applied plant research where agile, multi-focused and knowledge-driven approaches to protect crops, better manage resources or improve plant traits are needed.

As global populations increase and relative crop yields decline, plant researchers are looking for ways to increase crop production. Their efforts are further complicated by ongoing soil and environmental degradation, loss of agricultural land, climate instability and lack of genetic diversity in breeding programs. At the same time, new types of tools to assess target performance and plant quality monitoring are constantly emerging. High-throughput methods (omics, NGS or high-throughput phenotyping technologies) are increasingly used in plant and crop science to increase the speed of research and discovery. These techniques generate huge amounts of data in addition to the prior knowledge in public databases (covering genes, proteins, phenotypic information, literature and more).

The BioXM Knowledge Management Environment is an ideal platform to semantically integrate these diverse layers of information and map different entities and layers to each other. The system simplifies mining of all information for patterns — across different levels and diverse data sources (from global drought patterns to core genomes to SNP analysis) — and provides the opportunity to act on and profit from the knowledge gained in organizational plant research. Beyond exploring plant genotype-phenotype relationships, the Biomax approach supports collaborative genome comparison and modification that includes the integration of all knowledge and business assets.

The BioXM platform delivers robust and sustainable technology that integrates comprehensive knowledge assets and evolves as new information, research methods, monitoring tools and requirements emerge.

Use case: BioXM Knowledge Management in Plant Genomics

×

Genome Analysis

The accuracy and richness of genome annotation are important, and often critical, to further research and biological interpretation. With over fifteen years of experience in genome analysis for both industry and academia, the Biomax annotation team represents one of the most skilled and experienced genome analysis teams available.

Expert genome analysis ensures high-quality, comprehensive annotation of genome sequences and entire genomes. With Biomax genome analysis, state-of-the-art methods are combined with manual correction to guarantee optimal gene prediction for prokaryotes or eukaryotes. Functional and structural classification is assigned. The genome knowledge repository is cross-referenced to public and proprietary databases. Additional manual annotation expands and verifies the automatically generated data.

Biomax offers the following levels of genome analysis, which can be tailored to any specific research perspectives and goals:

Use cases: published annotation projects

×

Synthetic Biology

Synthetic biology is one of the most rapidly growing segments at Biomax. Cost-effective DNA sequencing and de novo DNA synthesis have facilitated the emergence and rapid evolution of synthetic biology. The development of DNA assembly standards, publicly available parts registers for sharing bioparts and computer-aided design (CAD) tools have been instrumental in accelerating discovery.

Biomax synthetic biology solutions address the challenges of putting this innovation to good use. With enterprise-level knowledge management platforms that empower new and emerging molecular technologies, Biomax helps clients meet the challenges of R&D process efficiency and productivity in many areas:

Biomax technology allows researchers to visualize, study, create and alter highly complex pathways and DNA sequences. The BioXM Knowledge Management Environment facilitates the detailed characterization of bioparts with respect to sequence information, part function and performance. Researchers can better assess the quality of the parts and use them to design biological systems targeting the desired functionality. Perhaps most importantly, the BioXM system allows researchers to fully leverage design-build-test-learn iterative approach to create improved biological systems.

Use case: Operational excellence in genetic engineering

×

CIRO+ and Biomax announce milestone medical and economic accomplishments after five years of cooperation

HORN, Netherlands and PLANEGG, Germany — (8 December 2015) —

CIRO+ (Center of expertise for chronic organ failure) and Biomax Informatics announce milestone medical and economic benefits resulting from their ongoing cooperation to deliver the most comprehensive, fully digital system for managed care in chronic lung failure. Business analysis revealed that CIRO+ doubled the number of patients treated at CIRO+ since 2006 while costs during the period went up by only 25%, thus realizing approximately 30% efficiency gain per patient. At the same time, patient outcomes were improved by 50%.

Professor Dr. Emiel Wouters, Chairman of the CIRO+ Board of Directors, links these successes to their ongoing collaboration with Biomax, which began five years ago. “Implementing our ambitious, multidisciplinary approach only became possible through the collaboration with Biomax. The Biomax BioXM system has been in routine use at CIRO+ clinics 24/7 for the past two years and has allowed us to scale up most efficiently.”

CIRO+ and Biomax launched the CIRO+ Data Center, the first integrated patient-centric knowledge management system for patient stratification and targeted therapy in chronic obstructive pulmonary disease in 2012. Based on the BioXM™ Knowledge Management platform, the CIRO+ Data Center helps the organization to better predict patient outcomes and optimize therapy for their patients.

“Biomax is very excited about the medical and economic benefits generated for CIRO+,” says Biomax CEO, Dr. Klaus Heumann. “CIRO+ is proof that investing in knowledge management as a medical backbone is workable and viable both medically and financially. Being the best in delivering the vision of Healthcare 3.0 is our mission. The cooperation with CIRO+ has accomplished this in an outstanding way; it sets the stage for a paradigm shift in complex and chronic disease care that masters the challenges of an aging society without compromising the quality of care for the patient.”

About CIRO+

CIRO+ (Horn, Netherlands), is an international center of excellence for the diagnosis and treatment of people with chronic obstructive pulmonary disease (COPD). To date, CIRO+ is considered the world leader in personalized pulmonary rehabilitation. More information about CIRO+ is available at www.ciro-horn.nl

About Biomax

Biomax Informatics AG (Planegg, Germany), founded in 1997, is a leader in the development of computational solutions for the life sciences. Biomax developed the BioXM™ Knowledge Management Environment and markets the Viscovery technology for better decision making and knowledge management in patient stratification and targeted medicine. More information about Biomax is available at www.biomax.com.

×

BIOMAX INFORMATICS announces expansion of long-term business relationship with DSM to develop novel bioinformatics solutions for life sciences R&D

PLANEGG, Germany — (19 July 2011) —

Biomax Informatics today announced the expansion of its long-term licensing and services agreement with Royal DSM to include solutions for synthetic biology using Biomax’s BioXM™ Knowledge Management Environment. The BioXM system is a unique generic software platform for dynamic modeling, visualization and analysis of biological and biomedical networks. By enabling an agile process to develop new life science applications through easy configuration and customization, the BioXM system allows new solutions to be deployed quickly to large user communities. Leveraging the capabilities of the BioXM system in synthetic biology allows a purpose-oriented engineering approach.

“DSM, as a science-based company in health, nutrition and materials, stands for innovation,” Dr. Hans Roubos, Senior Scientist at DSM, said. “We are committed to on-going exploration of new frontiers in science and technology as a basis for sustainable growth. Leveraging best-in-class technology, such as BioXM, is part of that strategy.”

Biomax Informatics has been working with DSM since 1998. DSM had early access to the next generation of the BioXM system. Released in March 2011, BioXM version 4 further simplifies the rollout of dedicated solutions by adding a customizable web portal builder that allows quick publishing of BioXM-based applications on the Web.

“By now we have used the new BioXM system in several different areas,” said Dr. Marco de Groot, Scientist Bioinformatics at DSM. “The system is outstanding in terms of flexibility and its ability to be tuned to our needs. Its solution-building approach is unprecedented: rolling-out a new application to hundreds of end-users takes only weeks. Most importantly, we are able to continuously adapt the system while staying in production, which greatly reduces cost.”

“We are excited to see the use of our BioXM platform expanding to the field of synthetic biology,” Dr. Klaus Heumann, CEO of Biomax Informatics, added. “The ability to combine scientific excellence and ease of use in a unified, sustainable platform with a highly agile solution-building process makes the BioXM Knowledge Management Environment unique — and makes all the difference for our customers.”

About DSM

Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

About Biomax

Biomax Informatics AG (Planegg, Germany), founded in 1997, is a leader in the development of customized bioinformatics solutions. Biomax developed the well-known Pedant-Pro™ Sequence Analysis Suite, the BioRS™ Integration and Retrieval System, the BioXM™ Knowledge Management Environment and other computational solutions for better decision making and knowledge management in the life science industry. In 2007 Biomax acquired the Viscovery data mining business from eudaptics gmbh to complement the BioXM system with tools to identify and validate diagnostic biomarkers. More information about Biomax can be found at www.biomax.com.

About the BioXM™ Knowledge Management Environment

The BioXM™ Knowledge Management Environment is a project-centered, distributed software platform that provides a central inventory of information and knowledge. Users create, manage and visualize scientific models as an extendible network of interrelated concepts. The BioXM platform facilitates communication and collaboration across research & development departments and integrates seamlessly into existing IT environments. More information about the BioXM platform can be found at www.biomax.com/bioxm.

×

BIOMAX INFORMATICS longtime customer KWS SAAT extends software license agreement

PLANEGG, Germany — (7 May 2014) —

Biomax Informatics AG and client KWS SAAT AG announce an extension of their software license agreement. KWS has licensed Biomax’s Pedant-Pro™ Sequence Analysis Suite to support their high-throughput analysis and annotation of plant and fungal sequences for many years.

According to Dr. Andreas Menze, head of bioinformatics at KWS, the company uses the Pedant-Pro™ software as one central component of their bioinformatics platform for functional and structural annotation of plant and fungal-based genomic and cDNA sequences. He explained that the Pedant-Pro™ system provides high-throughput analysis on a continuously increasing high number of sequences using a server cluster architecture. The analysis results are integrated into KWS data resources, made available for visualization applications and further analyses, and populate a knowledge-based platform that provides further associations and, thus, further insight for decision making, he said.

According to Menze, the system has proven its worth to KWS: “In addition to the Pedant-Pro™ system’s broad range of functionality and diverse integrated databases, the software has a very user-friendly GUI, which allows even staff with little IT experience to use the system efficiently.”

"Such a review after so many years from one of our longtime clients is the best proof of long term customer satisfaction in terms of usability, analysis reliability and scientific excellence. The Pedant-Pro™ system has been adapted continuously to address the needs of the ever-increasing amounts of sequences generated by next generation sequencing technologies. A tight integration of the Pedant-Pro™ system into our BioXM™ Knowledge Management Environment is the most recent and logical step in this process. We are pleased KWS has confirmed their satisfaction by extending our collaboration,” said Dr. Philipp Krubasik, Director of Key Accounts at Biomax.

About the Pedant-Pro™ software

The Pedant-Pro™ Sequence Analysis Suite provides fast, enterprise-scale annotation of individual sequences and complete genomes. Through numerous state-of-the-art analysis methods, the Pedant-Pro™ suite performs exhaustive prediction and characterization of genes and genetic elements (e.g., rRNAs, tRNAs, transposons) and functional and structural classification. The initial automatic data analysis can be supplemented by convenient manual annotation. The resulting Pedant-Pro™ database represents a comprehensive sequence, gene and protein repository with extensive information from public and proprietary data sources for each coding entity.

About Biomax

Biomax provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes companies and research organizations that are successful in drug discovery, diagnostics, fine chemicals, food and plant production. Further information is available at www.biomax.com.

About KWS SAAT AG

KWS is one of the world's leading plant breeding companies. More than 4,400 employees in 70 countries generated net sales of over €1.1 Billion in the fiscal 2012/13. For more than 150 years KWS has been managed as a family oriented and independent company. Main areas of its work are the breeding of varieties and the production and sale of seed for corn, sugar beet, cereals, potatoes, oil-seed rape and sunflower. 15 percent of its annual sales is invested in research and development. KWS uses state-of-the-art plant breeding methods and technologies to continuously improve variety yields and resistances to diseases, pests and abiotic stress. Further information: www.kws.com.

×

BIOMAX INFORMATICS collaborates with Pierre Fabre to provide a research environment to support therapeutic antibody development

PLANEGG, Germany — (18 June 2015) —

Biomax Informatics AG and Pierre Fabre announce a collaboration to create an integrated antibody sequence and knowledge database. Following a successful pilot project, Pierre Fabre has licensed Biomax’s BioXM™ Knowledge Management Environment and agreed on a continuous refinement and expansion of the system for comprehensive support of their antibody development process

Biomax used their BioXM™ Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre’s antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have quickly adopted the platform to collect and generate further knowledge.

“We have improved our database quality by a centralized bioinformatics system tailored to our needs in analyzing and validating our antibody discovery data,” said Dr. M. Tesar, Head of the Molecular and Cellular Department at Pierre Fabre Immunology Center. “We were impressed how quickly Biomax took our experts’ concepts and turned them into a software solution that efficiently supports our daily work. The improvement to our antibody R&D process has been invaluable.”

“This project represents exactly what Biomax strives to do: give researchers the tools that help them leverage their big concepts, capture knowledge and add value to their research,” said Dr. Philipp Krubasik, Director of Key Accounts at Biomax. “The BioXM platform was developed to be a flexible knowledge management system that can be configured to any area within life sciences to provide sustainable research support. We’re pleased that Pierre Fabre sees the potential to expand this project to support multiple disciplines along their complete antibody development pipeline.”

About the BioXM Knowledge Management platform

The BioXM Knowledge Management Environment is a project-centered, distributed software platform that provides a central inventory of information and knowledge. Users create, manage and visualize scientific models as an extendible network of interrelated concepts. The BioXM system facilitates communication and collaboration within research environments, allowing researchers to focus on science.

About Biomax

Biomax provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes companies and research organizations that are successful in drug discovery, diagnostics, fine chemicals, food and plant production. Further information is available at www.biomax.com.

About Pierre Fabre

Pierre Fabre is the third largest French pharmaceutical group. In 2013, its sales reached €2.008 billion, with international revenues accounting for 56%. Founded and still based in southwest France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.

Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide. In 2013, Pierre Fabre allocated more than 17% of its drug revenues to R&D, focusing on three main areas: oncology, dermatology and neuropsychiatry.

×

Sophic, Biomax and IBM Team to Win Syngenta Global Bioinformatics Data Integration Evaluation

Falmouth, MA – November 30 2005 -

Sophic Systems Alliance Inc. today announced that the integrated Biomax Informatics AG and IBM team won a competitive evaluation to provide Syngenta with a global data integration system. “Sophic is a systems integrator and last year, we launched a campaign with Biomax to win the Syngenta Biotechnology, Inc. (“Syngenta”) evaluation where six companies were vying for their business,” said Patrick Blake, CEO of Sophic. “Syngenta is one of the world’s largest agribusinesses with over 20,000 employees in 90 locations globally so winning their business was significant. Their evaluation team conducted an extensive proof of concept test for all vendors. Sophic, Biomax and IBM came together to demonstrate the unique strengths of the integrated Biomax BioRS™ and IBM WebSphere Information Integrator solution to provide Syngenta with a cutting edge global research environment.”

“We were pleasantly surprised to see how well they worked as a team and they clearly demonstrated the breadth and depth of the combined BioRS and IBM WebSphere Information Integrator solution,” said Dr. John Chan, Syngenta’s Head of Global Bioinformatics. “We concluded that by combining Biomax and IBM technology, we would meet or exceed all of the objectives outlined in our requirements document.” He went on to say that, “Over the next six months, we will deploy BioRS and WebSphere Information Integrator globally to provide Syngenta with a solid foundation for supporting our research.”

“We conducted a detailed review of all features, functions, flexibility, performance, quality, and technical excellence for all vendors,” said Dr. Michael Peterson, the Syngenta Head of Bioinformatics System Development. “In the end, we found that BioRS was an outstanding system for integrating public and internal scientific databases, and when combined with the additional capabilities of IBM WebSphere® Information Integrator, we had a world-class data integration platform.” Over a year ago, IBM developed a wrapper for integrating BioRS with WebSphere Information Integrator, providing an efficient way to combine the capabilities of the systems.

Dr. Klaus Heumann, President of Biomax Informatics AG, the developer of BioRS, said, “We have years of experience providing large companies with BioRS as their global data integration engine. However, the detailed scrutiny of the Syngenta process was the most thorough stress test we have ever seen. We are proud of our development team for delivering competitive, high performance software.” He concluded with “Our long-term relationship with Sophic Systems Alliance Inc, our integrator in the US, allows us to efficiently pursue and service large global accounts such as Syngenta.”

Mr. Kirk Sudheimer, the IBM Account Executive, said, “It was great to team with Sophic, a longtime IBM Optimized Business Partner, to compete for and win an account like Syngenta. The combined BioRS and WebSphere Information Integrator solution is truly superior technology and it’s great to have this opportunity to work together. This team win at Syngenta demonstrates our ability to configure and deliver a state of the art global bioinformatics data integration platform.”

About Sophic Systems Alliance.

Sophic Systems Alliance Inc. (SSA) is an integrator of bioinformatics software development companies and provides a full range of professional services. SSA sells, markets, implements and supports the delivery of a broad range of software modules developed by Biomax Informatics AG, Geospiza, Inc. and other members of the alliance. The company is focused on providing professional services to scientists and agencies in Washington, D.C. including scientific consulting and custom bioinformatics software development. Customers include government research organizations, pharmaceuticals, and biotech companies. SSA is an Optimized IBM Business Partner. More information is available at www.sophicalliance.com.

About Biomax

Biomax, a recognized pioneer in the development of customized bioinformatics solutions, was founded in 1997 as a spin-off of the GSF-MIPS academic research group, now the German Research Center for Environment and Health-Institute for Bioinformatics (GSF-IBI). Founded by Prof. Dr. H. W. Mewes, Prof. Dr. D. Frishman and Dr. K. Heumann, Biomax developed a broad portfolio of bioinformatics solutions, including the well-known Pedant-Pro™ Sequence Analysis Suite, the BioRS™ Data Integration and Retrieval System, and other bioinformatics tools and services used in metabolic analysis, proteomics, and gene expression analysis. Additional information about Biomax can be found at the company’s site on the World Wide Web at www.biomax.com.

About IBM.

The goal of IBM Healthcare and Life Sciences is to rapidly bring real-life business and information technology solutions to customers in the fields of pharmaceutical research and development, compliance, biotechnology, genomics, information-based medicine, biomedical imaging, healthcare delivery and other specialties. IBM is a proven leader in data integration, supercomputing, high performance storage, and on demand information technology services. Together with our Business Partners, IBM can provide customized, effective solutions that include hardware, software, services and the brightest ideas in the business. To learn more about IBM Healthcare and Life Science solutions and IBM Business Partners, visit ibm.com/industries/healthcare or contact an IBM Healthcare and Life Sciences specialist at LS@us.ibm.com.

×

BIOMAX INFORMATICS AG licenses the BioRS Integration and Retrieval System to Boehringer Ingelheim

MARTINSRIED, Germany — (9 October 2007) —

Biomax Informatics AG announced today that Boehringer Ingelheim GmbH & Co. KG has licensed the BioRS™ Integration and Retrieval System. Boehringer Ingelheim plans to use the BioRS system as a data integration platform providing unified access to public and proprietary data sources in its global pharmaceutical R&D environment.

About Biomax

Biomax Informatics AG (Martinsried, Germany), founded in 1997, is a leader in the development of customized bioinformatics solutions. Biomax developed the well-known Pedant-Pro™ Sequence Analysis Suite, the BioRS™ Integration and Retrieval System, the BioXM™ Knowledge Management Environment and other computational solutions for better decision making and knowledge management in the life science industry. Additional information about Biomax can be found at the company's site on the World Wide Web at www.biomax.com.

About the BioRS Integration and Retrieval System

The BioRS Integration and Retrieval System quickly and efficiently retrieves biological data from public and proprietary databases. Multiple databases can be searched simultaneously using convenient Web interfaces. Flat-file and relational databases (Oracle, MySQL) are easily integrated using Web or command-line interfaces and standardized data formats based on Extensible Markup Language (XML).

Biomax, BioRS, BioXM, and Pedant-Pro are registered trademarks of Biomax Informatics AG in Germany and other countries. MySQL is a trademark of MySQL AB. Oracle is a registered trademark of Oracle Corporation. Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.

×

Specialist Quality Assurance Life Science Software (m/w)

Biomax Informatics entwickelt innovative Software-Produkte und -Lösungen basierend auf einer konfigurierbaren, vielseitig erweiterbaren Knowledge Management Plattform. Unser Geschäft basiert auf Kundenorientierung, maßgeschneiderten Lösungen, Einfachheit und funktionellem Mehrwert in einem wissenschaftlich geprägten Umfeld. Unser tiefgreifendes Fachwissen und Kundenverständnis erlaubt uns in enger Zusammenarbeit mit unseren Kunden immer wieder innovative Lösungen in kürzester Zeit zur Produktionsreife zu entwickeln.

Für unseren Standort Planegg bei München sucht Biomax zum nächstmöglichen Zeitpunkt eine/n Mitarbeiter/in mit Hochschulabschluss im Bereich Lebenswissenschaften.

Ihre Aufgaben

Ihr Profil

Wir bieten Ihnen eine abwechslungsreiche, herausfordernde und verantwortungsvolle Tätigkeit in einer Organisation mit flachen Strukturen und schnellen Entscheidungswegen in einem angenehmen und kollegialen Umfeld. Wenn wir Ihr Interesse geweckt haben, senden sie bitte Ihre vollständigen Bewerbungsunterlagen per email unter Angabe des Stichwortes “Specialist QA Life Science Software” an: career@biomax.com.

×

Privacy Policy

This Privacy Policy governs the manner in which Biomax Informatics AG collects, uses, maintains and discloses information collected from users (each, a “User”) of the www.biomax.com website (“Site”). This privacy policy applies to the Site and all products and services offered by Biomax Informatics AG.

Personal identification information

We may collect personal identification information from Users in a variety of ways in connection with activities, services, features or resources we make available on our Site. Users may visit our Site anonymously. We will collect personal identification information from Users only if they voluntarily submit such information to us. Users can always refuse to supply personally identification information, except that it may prevent them from engaging in certain Site-related activities.

Non-personal identification information

We may collect non-personal identification information about Users whenever they interact with our Site. Non-personal identification information may include the browser name, the type of computer and technical information about Users means of connection to our Site, such as the operating system and the Internet service providers utilized and other similar information.

Web browser cookies

Our Site may use “cookies” to enhance User experience. User’s web browser places cookies on their hard drive for record-keeping purposes and sometimes to track information about them. User may choose to set their web browser to refuse cookies, or to alert you when cookies are being sent. If they do so, note that some parts of the Site may not function properly.

How we use collected information

Biomax Informatics AG may collect and use Users personal information for the following purposes:
To send periodic emails
We may use the email address to to response to their inquiries, questions. It may also be used to respond to their inquiries, questions, and/or other requests. If User decides to opt-in to our mailing list, they will receive emails that may include company news, updates, related product or service information, etc. If at any time the User would like to unsubscribe from receiving future emails, we include unsubscribe instructions at the bottom of each email or User may contact us via our Site.

How we protect your information

We adopt appropriate data collection, storage and processing practices and security measures to protect against unauthorized access, alteration, disclosure or destruction of your personal information, username, password, transaction information and data stored on our Site.

Sharing your personal information

We do not sell, trade, or rent Users personal identification information to others.

Third party websites

Users may find advertising or other content on our Site that link to the sites and services of our partners, suppliers, advertisers, sponsors, licensors and other third parties. We do not control the content or links that appear on these sites and are not responsible for the practices employed by websites linked to or from our Site. In addition, these sites or services, including their content and links, may be constantly changing. These sites and services may have their own privacy policies and customer service policies. Browsing and interaction on any other website, including websites which have a link to our Site, is subject to that website’s own terms and policies.

Changes to this privacy policy

Biomax Informatics AG has the discretion to update this privacy policy at any time. And when we do, we will revise the updated date at the bottom of this page. We encourage Users to frequently check this page for any changes to stay informed about how we are helping to protect the personal information we collect. You acknowledge and agree that it is your responsibility to review this privacy policy periodically and become aware of modifications.

Your acceptance of these terms

By using this Site, you signify your acceptance of this policy. If you do not agree to this policy, please do not use our Site. Your continued use of the Site following the posting of changes to this policy will be deemed your acceptance of those changes.

Contacting us

If you have any questions about this Privacy Policy, the practices of this site, or your dealings with this site, please contact us www.biomax.com/contact
Biomax Informatics AG
Robert-Koch-Str. 2
D-82152 Planegg
Germany

Call: +49 89 895574-0
info@biomax.com